SCH58261

Catalog No.S8104

For research use only.

SCH 58261 is a potent and selective A2a adenosine receptor antagonist with Ki of 2.3 nM and 2 nM for rat A2a and bovine A2a, respectively.

SCH58261 Chemical Structure

CAS No. 160098-96-4

Selleck's SCH58261 has been cited by 5 Publications

Purity & Quality Control

Choose Selective Adenosine Receptor Inhibitors

Biological Activity

Description SCH 58261 is a potent and selective A2a adenosine receptor antagonist with Ki of 2.3 nM and 2 nM for rat A2a and bovine A2a, respectively.
Targets
bovine A2a [1] rat A2a [1]
2.0 nM(Ki) 2.3 nM(Ki)
In vitro

SCH 58261 causes the inhibition of rabbit platelet aggregation and porcine coronary artery relaxation by antagonizing competitively the effects induced by CGS 21680. [1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HEK293 MVjGeY5kfGmxbjDhd5NigQ>? MXy2NEBucW6| M4O4c2Rqe3CuYXPlcYVvfCCxZjDbN2heS0eVMkG2PFAh\nKxbTDoeY1idiCjZHXuc5NqdmViQULBJJJm[2WydH;yJIV5eHKnc4Pl[EBqdiCKRVuyPVMh[2WubIOgZYZ1\XJiNkCgcYlveyCkeTDsbZF2cWRic3PpcpRqdGyjdHnvckBkd3WwdHnu[{BidmGueYPpd{whU2liPTCwMlAxODZizszNMi=> NULzUWJMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOyNFAzPDNpPkKzNlAxOjR|PD;hQi=>
CHO M3nhS2Z2dmO2aX;uJIF{e2G7 NYW4cJIxTGm|cHzhZ4Vu\W62IH;mJHs{UF1vU1PIMUA2QDJ4MTDmdo9uKGi3bXHuJGFl\W6xc3nu[UBCOkFicnXj[ZB1d3JiZYjwdoV{e2WmIHnuJGNJVyClZXzsd{whU2liPTCwMlAxOTFizszNMi=> M1LTTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493Nzl4MkK1OVQoRjl4MkK1OVQ9N2F-
HEK293 NW\CTnBvTnWwY4Tpc44h[XO|YYm= NIfyVWlFcXOybHHj[Y1mdnRib3[gd5Bm[2moaXOgX|NJZS2VQ1itJFU5OjZzIHLpcoRqdmdiYYSgbJVu[W5iQXTlco9{cW6nIFGyRUBz\WOncITvdkBmgHC{ZYPz[YQhcW5iSFXLNlk{KGOnbHzzMkwhU2liPTCwMlAxOTFizszNMi=> NIfpSng9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zMUe1OFU5Oyd-MUG3OVQ2QDN:L3G+
CHO NInaT5JHfW6ldHnvckBie3OjeR?= M4\oV2Rqe3CuYXPlcYVvfCCxZjDbN2heVkWFQTDmdo9uKGi3bXHuJIFl\W6xc3nu[UBCOkFicnXj[ZB1d3JiZYjwdoV{e2WmIHnuJGNJVyClZXzsd{whU2liPTCwMlAxOTFizszNMi=> NVrTOHR4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm1NFE2OTNpPkG5OVAyPTF|PD;hQi=>
CHO NEft[3JHfW6ldHnvckBie3OjeR?= NFnkN4M3OCCvaX7z NGX5dIRFcXOybHHj[Y1mdnRib3[gX|NJZS2cTTCyOFE{QDViZoLvcUBpfW2jbjDh[IVvd3OrbnWgRVJCKHKnY3XweI9zKGW6cILld5Nm\CCrbjDDTG8h[2WubIOgZYZ1\XJiNkCgcYlveyCkeTDsbZF2cWRic3PpcpRqdGyjdHnvckBkd3WwdHnu[{whU2liPTCwMlAxOTFizszNMi=> M33PSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{MkC0O|M6Lz5{MkKwOFc{QTxxYU6=
HEK293 MoXDSpVv[3Srb36gZZN{[Xl? NITZUoE3OCCvaX7z MU\EbZNxdGGlZX3lcpQhd2ZiW{PIYXpOOjRzM{i1JIZzd21iaIXtZY4h[WSnbn;zbY5mKEF{QTDy[YNmeHSxcjDlfJBz\XO|ZXSgbY4hUEWNMkmzJINmdGy|IHHmeIVzKDZyIH3pcpMh[nlicnHwbYQh\mmudILheIlwdiCjc4PhfUwhU2liPTCwMlAxOTJ|IN88UU4> M2LvNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyM{CzO|cyLz5{MEOwN|c4OTxxYU6=
HEK293 NWD3dYUzTnWwY4Tpc44h[XO|YYm= NHrVRVk3OCCvaX7z MoHmR49ueGW2aYTpeoUh[mmwZHnu[{Bi\m[rbnn0fUB1dyCqdX3hckBi\GWwb4PpcoUhSTKDIILlZ4VxfG:{IHX4dJJme3OnZDDpckBJTUt{OUOgZ4VtdHNiYX\0[ZIhPjBibXnud{BjgSCobIXvdoV{[2WwY3WgdI9t[XKrenH0bY9vKGG|c3H5JIlvKHC{ZYPlcoNmKG:oIF3SV|U{PDZuIFvpJF0hOC5yMEG5JO69VS5? NHmwUGI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{KwNFI1Oyd-MkOyNFAzPDN:L3G+
CHO M2PqNWZ2dmO2aX;uJIF{e2G7 M1yyfmRqe3CuYXPlcYVvfCCxZjDbN2heS0iDIH\yc40hcHWvYX6gRYRmdm:|aX7lJGEyKHKnY3XweI9zKGW6cILld5Nm\CCrbjDDTG8h[2WubIOsJGtqKD1iMD61OFkh|ryPLh?= NEjs[Xc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi97NkKyOVU1Lz57NkKyOVU1RC:jPh?=
CHO MVzGeY5kfGmxbjDhd5NigQ>? M3u4ZmRqe3CuYXPlcYVvfCCxZjDzdIVkcW[rYzDbN2heTFCFUGigZolv\GmwZzDheEBpfW2jbjDB[IVvd3OrbnWgRVEhemWlZYD0c5Ih\XiycnXzd4VlKGmwIFPIU{Bk\Wyucz6sJGtqKD1iMD61OFkh|ryPLh?= NYDhOWx{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUG3OVQ2QDNpPkGxO|U1PTh|PD;hQi=>
CHO M17oUmZ2dmO2aX;uJIF{e2G7 NImweIQyOjBibXnudy=> Ml[zSIl{eGyjY3Xt[Y51KG:oIGuzTH0uTFCFUGig[pJwdSCqdX3hckBi\GWwb4PpcoUhSTFicnXj[ZB1d3JiZYjwdoV{e2WmIHnuJGNJVyClZXzsd{Bi\nSncjCxNlAhdWmwczDifUBtcXG3aXSgd4NqdnSrbHzheIlwdiClb4XueIlv\yxiS3mgQUAxNjV2OTFOwG0v NHTvdXk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkKwOFc{QSd-MkKyNFQ4Ozl:L3G+
HEK293 MXvGeY5kfGmxbjDhd5NigQ>? M{O4[VYxKG2rboO= NUe2cFF5TGm|cHzhZ4Vu\W62IH;mJHs{UF2GUFPQXEBnem:vIHj1cYFvKGGmZX7vd4lv\SCDMTDy[YNmeHSxcjDlfJBz\XO|ZXSgbY4hUEWNMkmzJINmdGy|IHHmeIVzKDZyIH3pcpMh[nlicnHwbYQh\mmudILheIlwdiCjc4PhfUwhU2liPTCwMlU6PDFizszNMi=> MoHVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB|MEO3O|EoRjJyM{CzO|cyRC:jPh?=
HEK293 NGTleoxHfW6ldHnvckBie3OjeR?= NYXLZnN7TGm|cHzhZ4Vu\W62IH;mJHs{UF1vQVKgUWVESSCocn;tJIh2dWGwIFHk[Y5we2mwZTDBN{Bz\WOncITvdkBmgHC{ZYPz[YQhcW5iSFXLNlk{KGOnbHzzMEBMcSB;IEGg{txONg>? MkC1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTJ4NE[wN|MoRjF{NkS2NFM{RC:jPh?=
HEK293 NGqwd4FHfW6ldHnvckBie3OjeR?= MUPEbZNxdGGlZX3lcpQhd2ZiW{GyOWleSUJvTVXDRUBnem:vIHj1cYFvKEGmZX7vd4lv\SCDMzDy[YNmeHSxcjDlfJBz\XO|ZXSgbY4hUEWNMkmzJINmdGy|LDDLbUA:KDFyIN88UU4> M3jxdlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493Nzl4MkK1OVQoRjl4MkK1OVQ9N2F-
HEK293 MUPGeY5kfGmxbjDhd5NigQ>? Mnm0SIl{eGyjY3Xt[Y51KG:oIIPw[YNq\mmlIGuzTH1FWEOSWDDibY5lcW6pIHH0JIh2dWGwIHHk[Y5we2mwZTDBNmIhemWlZYD0c5Ih\XiycnXzd4VlKGmwIFjFT|I6OyClZXzsd{4tKEurIE2gNVAh|ryPLh?= NVXxT3JZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUG3OVQ2QDNpPkGxO|U1PTh|PD;hQi=>
CHO M1XYOWZ2dmO2aX;uJIF{e2G7 NVPi[4c2TGm|cHzhZ4Vu\W62IH;mJJNx\WOrZnnjJHs{UF2PUlWzNFA5NUZ{MDDibY5lcW6pIHH0JIh2dWGwIHHk[Y5we2mwZTDBN{Bz\WOncITvdkBmgHC{ZYPz[YQhcW5iQ1jPJINmdGy|LjygT4khRSBzMDFOwG0v MkDjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTF5NUS1PFMoRjFzN{W0OVg{RC:jPh?=
CHO NVXrenB4TnWwY4Tpc44h[XO|YYm= MX\EbZNxdGGlZX3lcpQhd2ZiW{PIYW5GS0FiZoLvcUBpfW2jbjDh[IVvd3OrbnWgRVMhemWlZYD0c5Ih\XiycnXzd4VlKGmwIFPIU{Bk\WyuczygT4khRSBzMDFOwG0v NEm3TFk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUWwNVUyOyd-MUm1NFE2OTN:L3G+
CHO NWDPeoZDTnWwY4Tpc44h[XO|YYm= MVWxNlAhdWmwcx?= NGLrdG1FcXOybHHj[Y1mdnRib3[gX|NJZS2PUlWtN|AxQC2IMkCg[pJwdSCqdX3hckBi\GWwb4PpcoUhSTNicnXj[ZB1d3JiZYjwdoV{e2WmIHnuJGNJVyClZXzsd{Bi\nSncjCxNlAhdWmwczDifUBtcXG3aXSgd4NqdnSrbHzheIlwdiClb4XueIlv\yxiS3mgQUAyOCEQvF2u NVLxcmpZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKyNFQ4OzlpPkKyNlA1PzN7PD;hQi=>
HEK293 MoXBSpVv[3Srb36gZZN{[Xl? MWq2NEBucW6| MnO2SIl{eGyjY3Xt[Y51KG:oIGuzTH0uTFCFUGig[pJwdSCqdX3hckBi\GWwb4PpcoUhSTKEIILlZ4VxfG:{IHX4dJJme3OnZDDpckBJTUt{OUOgZ4VtdHNiYX\0[ZIhPjBibXnud{whU2liPTCxNEDPxE1w M2DyZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{MkC0O|M6Lz5{MkKwOFc{QTxxYU6=
HEK293 MoXYSpVv[3Srb36gZZN{[Xl? MVOxNFAhdk1? NXG3fXBrOjRiaILz M3O1d2FvfGGpb37pd5Qh[WO2aY\peJkh[XRiaIXtZY4h[WSnbn;zbY5mKEF{QTDy[YNmeHSxcjDlfJBz\XO|ZXSgbY4hUEWNMkmzJINmdGy|IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZiTlXDRU1qdmS3Y3XkJIlvfHKjY3XscJVt[XJiY1HNVEBi[2O3bYXsZZRqd25iYYSgNVAxKG6PIHHmeIVzKDJ2IHjyd{ApWn[kPTCwMlQxKHCvb3yvcYwq MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODNyM{e3NUc,OjB|MEO3O|E9N2F-
HEK293 Ml\qSpVv[3Srb36gZZN{[Xl? NGHsUogyKHWP MXWxOUBucW6| NVrnOmVbSW62YXfvcol{fCCjY4Tpeol1gSCjdDDoeY1idiCDMlGgdoVk\XC2b4Kg[ZhxemW|c3XkJIlvKEiHS{K5N{Bk\WyuczDhd5Nme3OnZDDhd{Bl\WO{ZXHz[UBqdiCQRVPBMYlv\HWlZXSgZ2FOWCC{ZXzlZZNmKGG2IEGgeW0h[W[2ZYKgNVUhdWmwcx?= M3HZSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|OUWzOlg3Lz5{M{m1N|Y5PjxxYU6=
In vivo In mice with Spinal cord injury, SCH58261 (0.01 mg/kg, i.p.) reduces demyelination and levels of TNF-α, Fas-L, PAR, Bax expression and activation of JNK MAPK. Chronic SCH58261 administration improves the neurological deficit up. [2] In rats with 6-OHDA-induced Parkinson's disease, SCH58261 (2 mg/kg, i.p.) improves the 6-OHDA-induced bradykinesia and motor disturbance. [3]

Protocol (from reference)

Animal Research:[2]
  • Animal Models: Mice with Spinal cord injury
  • Dosages: 0.01 mg/kg
  • Administration: i.p.

Solubility (25°C)

In vitro

In vivo

Add solvents to the product individually and in order
(Data is from Selleck tests instead of citations):
4% DMSO40% PEG 300+4% Tween 80++ddH2O
For best results, use promptly after mixing.

2mg/mL

Chemical Information

Molecular Weight 345.36
Formula

C18H15N7O

CAS No. 160098-96-4
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles C1=CC=C(C=C1)CCN2C3=C(C=N2)C4=NC(=NN4C(=N3)N)C5=CC=CO5

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy SCH58261 | SCH58261 supplier | purchase SCH58261 | SCH58261 cost | SCH58261 manufacturer | order SCH58261 | SCH58261 distributor